We recently updated our Privacy Notice and Terms of Use.
Increasing Physician Awareness of Pulmonary Arterial Hypertension in Systemic Sclerosis
E-Publication E-Publication

Increasing Physician Awareness of Pulmonary Arterial Hypertension in Systemic Sclerosis


Maximum Credits:


E-Publication E-Publication


Maximum Credits:
E-Publication E-Publication


Maximum Credits:

Overview: This online CME publication discusses guideline recommendations for pulmonary arterial hypertension (PAH) screening in patients with systemic sclerosis (SSc) and presents key insights on available treatment options for PAH. In addition, this publication is enhanced with audio clips from an expert roundtable discussion on the increased risk of PAH in SSc, signs and symptoms that should prompt further evaluation for PAH, and the importance of communication among the multidisciplinary team.

CME Information:

Lorinda Chung, MD, MS
Associate Professor of Medicine (Immunology and Rheumatology) and Dermatology
Stanford University School of Medicine
Stanford, CA

Ronald Oudiz, MD, FACP, FACC, FCCP
Professor of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Director, Liu Center for Pulmonary Hypertension
Los Angeles Biomedical Institute at Harbor-UCLA Medical Center
Los Angeles, CA

Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Baltimore, MD

Laura Rafferty
Managing Editor
Baltimore, MD

Amy Sison
Director of Continuing Medical Education
Baltimore, MD

Laura Trimingham, MD
Vashon, WA

Learning Objectives
Upon completion, participants should be able to:

  • Describe clinical and patient-related factors that are associated with an increased risk of PAH among patients with SSc
  • Be familiar with the PAH screening recommendations for patients with SSc
  • Facilitate an evidence-based, comprehensive evaluation for PAH among patients with SSc

Target Audience
This activity is intended for rheumatologists.

Series Overview/Statement of Need
Compared with the general population, patients with systemic sclerosis (SSc) are at an increased risk of developing pulmonary arterial hypertension (PAH). Early stage SSc-PAH is often clinically silent or presents with nonspecific symptoms, making it particularly challenging to identify. Research has shown that patients identified through screening can often be diagnosed with earlier-stage disease and experience improved outcomes compared with patients diagnosed through routine care or when symptomatic. Nevertheless, despite recommendations for routine PAH screening in patients with SSc, many patients experience diagnostic delays. Therefore, it is important to increase rheumatologists’ awareness about the need to screen for PAH in patients with SSc.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Original Release Date: July 14, 2017
Expiration Date: July 13, 2018
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
Lorinda Chung, MD, MS
Consulting fees/advisory boards: Actelion Pharmaceuticals Ltd., Reata Pharmaceuticals, Inc.
Contracted research: Bayer HealthCare Pharmaceuticals, United Therapeutics Corporation

Ronald Oudiz, MD, FACP, FACC, FCCP
Consulting fees/advisory boards: Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals, Gilead Sciences, Inc., Reata Pharmaceuticals, Inc., SteadyMed Therapeutics, Inc., United Therapeutics Corporation
Fees received for promotional/non-CME activities: Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics Corporation
Contracted research: Actelion Pharmaceuticals Ltd., Arena Pharmaceuticals Inc., Bayer HealthCare Pharmaceuticals, Eiger BioPharmaceuticals, Gilead Sciences, Inc., Reata Pharmaceuticals, Inc., SteadyMed Therapeutics, Inc., United Therapeutics Corporation

Laura Trimingham, MD
Ownership interest (stocks/stock options – excluding mutual funds): Juno Therapeutics

The peer reviewers and other activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or e-mail info@med-iq.com.

Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Microsoft Internet Explorer 8.0 or later

Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/

Google Chrome - latest version
Download: http://www.google.com/chrome

Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/

For technical support, go to https://www.med-iq.com/support-manual.html.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: https://www.Med-IQ.com/privacy-statement/.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Gilead Sciences, Inc.

© 2017 Med-IQ®. All rights reserved.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.